Skip to main content

Advertisement

SpringerLink
Log in

The Regulation of Biosimilars in Latin America

  • Biosimilars (E Mysler, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

This article summarizes the regulatory scenario on biological medications in Latin America focusing on comparability studies, extrapolation of indications, interchangeability and pharmacovigilance issues. In the case of comparability studies, what is being discussed is the possibility of decreasing the clinical trials requirement, but that the molecule should be well characterized in the studies of pharmacokinetics and pharmacodynamics. With the worldwide-level approval of the first monoclonal antibody biosimilar, infliximab, extrapolation of indications are being discussed, since the behavior of the Latin America regulatory agencies has been different with regard to such issue. Another issue discussed by the regulatory agencies is the interchangeability between biological medications and their biosimilars, mainly due to the fact that there is a clear confusion on interchangeability and substitution concepts. Finally, the pharmacovigilance debate, according to what takes place globally, is related to the need for identifying and differentiating the reference biological medication and its biosimilars for traceability purposes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Azevedo VF, Mysler E, Álvarez AA, Hughes J, Flores-Murrieta FJ, Ruiz de Castilla EM. Recommendations for the regulation of biosimilars and their implementation in Latin America. GaBI J. 2014;3(3):143–8. The expert panel’s perspectives on the current status led to six major recommendations in order to enhance the safe use of biosimilars in the Latin America region.

    Article  Google Scholar 

  2. Bian J, Armitage JO, Ray P, Ablin RJ, Hruskesky WJ, Hermanson T, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol. 2014;15(13):e594–605.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Regulation of similar biotherapeutic products in Latin America. Generics and Biosimilars Initiative. Published: Feb 8, 2013. http://gabionline.net/Biosimilars/Research/Regulation-of-similarbiotherapeutic-products-in-Latin-America Accessed November 2, 2015.

  4. Araujo DV. Consideraciones Regulatorias sobre Productos Biológicos en Brasil. Value Health Reg Issues. 2012;1(2):254–6.

    Article  Google Scholar 

  5. Argentinian guidelines for similar biological medicines. GaBI Online - Generics and Biosimilars Initiative. Global biosimilars guideline development – EGA’s perspective [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 May 3]. Available from: http://www.gabionline.net/Guidelines/Global-biosimilars-guideline-development-EGA-s-perspective Accessed November 2, 2015.

  6. Ministerio de Salud. Propuesta de norma y aspectos técnicos para la evaluación de productos farmacéuticos biotecnológicos derivados de técnicas ADN recombinantes. Santiago: Instituto de Salud Pública de Chile; 2011. Available from: http://www.ispch.cl/sites/default/files/documento/2011/11/Pro_Norma_Biotecnologicos.pdf. Accessed November 2, 2015.

    Google Scholar 

  7. Ministerio de Salud y Protección Social, Presidencia de la República de Colombia. Propuesta decreto para la reglamentación de productos biotecnológicos en Colombia. 2012. Available from: http://www.minsalud.gov.co/Normatividad/Proyecto%20Decreto%20Biologico%20-Biotecnologicos.pdf. Accessed November 2, 2015.

  8. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Resolução - RDC n° 55, de 16 de dezembro de 2010. Available from: http://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2010/res0055_16_12_2010.html Accessed December 21, 2015.

  9. Castanheira LG, Barbano DB, Rech N. Current development in regulation of similar biotherapeutic products in Brazil. Biologicals. 2011;39(5):308–11.

    Article  PubMed  Google Scholar 

  10. Estados Unidos Mexicanos - Secretaría de Salud. NORMA Oficial Mexicana NOM-257-SSA1-2014, En materia de medicamentos biotecnológicos. Available from: http://www.dof.gob.mx/nota_detalle.php?codigo=5375517&fecha=11/12/2014. Accessed December 21, 2015.

  11. Estados Unidos Mexicanos - Secretaría de Salud. NORMA Oficial Mexicana NOM-220-SSA1-2012, Instalación y operación de la farmacovigilancia. Available from: http://www.dof.gob.mx/nota_detalle.php?codigo=5284236&fecha=07/01/2013. Accessed December 21, 2015.

  12. Estados Unidos Mexicanos - Secretaría de Salud. NORMA Oficial Mexicana NOM-177-SSA1-2013. Available from: http://www.dof.gob.mx/nota_detalle.php?codigo=5314833&fecha=20/09/2013. Accessed December 21, 2015.

  13. República de Panamá. Ministerio de Salud. Decreto Ejecutivo 340 de 2007. Available from: http://panama.justia.com/federales/decretos-ejecutivos/340-de-2007-sep-6-2007/gdoc/ Accessed December 21, 2015.

  14. Costa Rica. Ministerio de Salud. Reglamento Técnico: RTCR 440: 2010. Reglamento de Inscripción y Control de Medicamentos Biológicos. Available from: http://www.pgrweb.go.cr/scij/Busqueda/Normativa/Normas/nrm_texto_completo.aspx?param1=NRTC&nValor1=1&nValor2=72232&nValor3=88031&strTipM=TC Accessed December 21, 2015.

  15. República de Guatemala. Ministério de Salud Pública y Asistencia Social. Registro Sanitario de Referencia de Productos Biológicos y Biotecnológicos. Available from: http://www.medicamentos.com.gt/index.php/legislacion-vigente/normas-tecnicas?start=20 Accessed December 21, 2015.

  16. World Health Organization. Guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology. In: WHO Expert Committee on Biological Standardization. Forty-first report. Genebra, World Health Organization, 1991, Annex 3 (WHO Technical Report Series, No. 814).

  17. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology—“O Brave New World”. Nat Rev Rheumatol. 2012;8:430–6.

    Article  CAS  PubMed  Google Scholar 

  18. Pineda C, Caballero-Uribe CV, de Oliveira MG, Lipszyc PS, Lopez JJ, Mataos Moreira MM, et al. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol. 2015;34(4):635–40. The group discussed current challenges and gaps in pharmacovigilance in Latin America, paying close attention to the major issues associated with traceability and pharmacovigilance of biosimilars following their approval.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Nonproprietary Naming of Biological Products Guidance for Industry, August 2015 http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm459987.pdf

Download references

Author information

Authors and Affiliations

  1. Latin American Center for Biological Research (CLAPBio), Rua São José, 696, Alto da Boa Vista, São Paulo, SP, Brazil, ZIP 04739-001

    Ricardo Garcia

  2. Internal Medicine Department at State University of Rio de Janeiro, Boulevard 28 de setembro 77, room 329, Vila Isabel, Rio de Janeiro, Brazil, ZIP 20551-030

    Denizar Vianna Araujo

Authors
  1. Ricardo Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Denizar Vianna Araujo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ricardo Garcia.

Ethics declarations

Conflicts of Interest

Ricardo Garcia and Denizar Vianna Araujo declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Biosimilars

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garcia, R., Araujo, D.V. The Regulation of Biosimilars in Latin America. Curr Rheumatol Rep 18, 16 (2016). https://doi.org/10.1007/s11926-016-0564-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-016-0564-1

Keywords

Search

Navigation